MedPath

Clinical phase II study of cisplatin plus gemcitabine followed by switch maintenance docetaxel for advanced squamous-cell lung cancer

Not Applicable
Conditions
pulmonary squamous-cellcarcinoma
Registration Number
JPRN-UMIN000004297
Lead Sponsor
Okayama Lung Cancer Study Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

pts with active co-morbidities including severe conditions of heart diseases, gastric ulcers, infections, uncontrollable diabetes, psychlogicai diseases, hypertension, active interstitial and hearing loss. pts with active other cancers pts with massive pleural and cardiac effusion and ascites that need to be immediately treated pts with symptomatic brain metastases

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath